Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CD274 positive |
| Therapy | Nivolumab |
| Indication/Tumor Type | glioblastoma |
| Response Type | no benefit |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 positive | glioblastoma | no benefit | Nivolumab | Clinical Study - Cohort | Actionable | In a retrospective analysis, response to Keytruda (pembrolizumab) or Opdivo (nivolumab) therapy was not predicted by RNA expression levels of CD274 (PD-L1) in glioblastoma patients (PMID: 30742119). | 30742119 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (30742119) | Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. | Full reference... |